Genetic cancer vaccines: Current status and perspectives

Luigi Aurisicchio, Gennaro Ciliberto

Research output: Contribution to journalArticle

Abstract

Introduction: The recent approval of the first therapeutic cancer vaccine by the US Regulatory Agency represents a breakthrough event in the history of cancer treatment. The past scepticism towards this type of therapeutic intervention is now replaced by great expectations. The field is now moving towards the development of alternative vaccination technologies, which are capable of generating stronger, more durable and efficient immune responses against specific tumour-associated antigens (TAAs) in combination with cheaper and more standardised manufacturing. Areas covered: In this context, genetic vaccines are emerging among the most promising methodologies. Several evidences point to combinations of different genetic immunisation modalities (heterologous prime/boost) as a powerful approach to induce superior immune responses and achieve greater clinical efficacy. In this review, we provide an overview of the current status of development of genetic cancer vaccines with particular emphasis on adenoviral vector prime/DNA boost vaccination schedules. Expert opinion: We believe that therapeutic genetic cancer vaccines have the strong potential to become an established therapeutic modality for cancer in next coming years, in a manner similar to what have now become monoclonal antibodies.

Original languageEnglish
Pages (from-to)1043-1058
Number of pages16
JournalExpert Opinion on Biological Therapy
Volume12
Issue number8
DOIs
Publication statusPublished - Aug 2012

Keywords

  • cancer vaccines
  • plasmid DNA
  • tumour-associated antigens
  • viral vectors

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Fingerprint Dive into the research topics of 'Genetic cancer vaccines: Current status and perspectives'. Together they form a unique fingerprint.

  • Cite this